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Abstract 
 
Introduction 
Group B streptococcus (GBS) is an important cause of neonatal sepsis 
worldwide. Data on the prevalence of maternal GBS colonisation, risk factors for 
carriage, antibiotic susceptibility, and circulating serotypes are necessary to 
tailor adequate locally relevant public health policies.  
Methods 
A prospective study including pregnant women and their newborns was 
conducted between March and July 2013 in Morocco. We collected clinical data 
and vagino-rectal and urine samples of recruited pregnant women, together with 
clinical characteristics and body surface samples of their newborns. Additionally, 
the first three newborns admitted every day with suspected invasive infection 
were recruited for a thorough screening of neonatal sepsis. Serotypes were 
characterised by molecular testing.  
Results 
A total of 350 pregnant women and 139 of their newborns were recruited. The 
prevalence of pregnant women colonised by GBS was 24%. In 5/160 additional 
sick newborns recruited with suspected sepsis, blood cultures were positive for 
GBS. Gestational hypertension and vaginal pruritus were significantly 
associated with a vagino-rectal GBS colonisation in univariate analyses. All the 
strains were susceptible to penicillin, while 7% were resistant to clindamycin 
and 12% to erythromycin. Most common GBS serotypes detected included V, II 
and III.  
 
Conclusions 
In Morocco, maternal GBS colonisation is high. Penicillin can continue being the 
cornerstone of intrapartum antibiotic prophylaxis. A pentavalent GBS vaccine 
(Ia, Ib, II, III, and V) would have been effective against the majority of the 
colonising cases in this setting, but the trivalent one (Ia, Ib and III) would only 
prevent 28% of the cases.  
 
Keywords: Streptococcus agalactiae, Group B Streptococcus, Morocco, 
antimicrobial resistance, risk factors, serotypes 
 
Abbreviations 
GBS: Group B streptococcus 
HER: Hôpital d’Enfants de Rabat 
ANC: Antenatal consultations 
NBS: Newborn body surface 
CHIS: Centre Hospitalier Universitaire Ibn Sina 
MIC: Minimal inhibitory concentration 
OR: Odds ratio  
CI: confidence interval 
MLST: multilocus sequence typing 
 
Introduction 
Group B streptococcus (GBS) is an important cause of neonatal sepsis 
worldwide and is associated with high mortality in low- and middle-income 
countries [1-3]. Maternal vagino-rectal GBS colonisation can lead to vertical 
transmission in utero or during childbirth, causing life-threatening neonatal 
infections [4]. To prevent vertical transmission of GBS, intrapartum antibiotics 
are recommended for women identified as GBS carriers through active 
screening conducted during the last trimester of pregnancy [5]. The incidence of 
early-onset GBS sepsis has notably decreased with this measure, but such a 
strategy is not effective against late-onset sepsis [6]. In certain countries, such 
as Morocco, GBS is not routinely screened in all pregnant women and 
intrapartum antibiotic prophylaxis is restricted to the recognition of determined 
risk factors as maternal fever, prolonged labour or prolonged rupture of 
membranes. For any of those strategies to work effectively, functional health 
systems and laboratory facilities are needed, something seldom available in the 
busy maternities of many middle- and low-income countries. 
 
An additional strategy to prevent early and late neonatal GBS disease is based 
on the concept of “vertical vaccination” of pregnant women, under the 
assumption that the antibodies generated after vaccination would be passively 
transferred to the newborn. Various GBS conjugate vaccines against some 
GBS capsular polysaccharides are currently being developed [7]. These 
polysaccharides have chemical and antigenic differences that define ten GBS 
capsular types (serotypes) and play a role as virulence factors being involved in 
different mechanisms for evading the host immune system. As an example, 
serotype III, and specifically its particular hypervirulent clone ST17, has been 
associated with a substantial proportion of invasive cases in infants [8, 9].   
In this paper, we aimed to investigate a) the prevalence of GBS colonisation in 
pregnant women, b) the risk factors for GBS carriage, c) the antibiotic 
susceptibility of GBS isolates and d) the circulating serotypes in Morocco. In 
spite of the paucity of GBS data from Morocco, this pathogen is believed to 
cause a significant amount of morbidity and mortality in this country; however, 
preventive strategies are often inexistent.  
 
Methods 
Study setting and recruitment 
A prospective study was conducted in the months of March to July 2013 in two 
different Moroccan hospitals: 1) the Maternité des Orangers, a public maternal 
tertiary level hospital in Rabat (Morocco); and 2) the neonatal unit of the Hôpital 
d’Enfants de Rabat (HER), the reference paediatric hospital for the country.  
 
During the study, study staff asked pregnant women at gestational age between 
35 and 37 weeks attending the general or high-risk antenatal consultations 
(ANC) whether they would be willing to participate in the study. “High risk 
pregnancy” was defined in this study as any given risk for the mother or foetus, 
identified by the obstetrician in charge. These included pre-existing chronic 
conditions or diseases of the mother, a previous unfavourable obstetric history, 
or other maternal, foetal or placental factors identified as potential risks to the 
outcome of the pregnancy. As some pregnant women may have failed to attend 
ANC during those weeks, an additional group of women (irrespective of 
gestational age upon arrival) were directly enrolled at the time of delivery if they 
arrived in labour without both rupture of membranes and visible haemorrhage. 
For all groups, women above 18 years, or with permission of a legal guardian if 
younger, who signed an informed consent and without known allergy to material 
used for obtaining samples, underwent the standardised procedures. Due to the 
limited capacity of the laboratory, only the first three pregnant women who met 
inclusion criteria were recruited at each site every day. 
Demographic, socio-economic and clinical data were collected into 
standardised questionnaires. One vagino-rectal and one vaginal swab were 
collected into Stuart transport medium according to standard methodologies [5] 
together with a urine sample and a vaginal smear. 
 
Follow-up 
Pregnant women recruited at the ANC were encouraged to attend the hospital 
for delivery. A unique identification number and a study card were given to them 
to facilitate the laboratory’s feedback at the time of delivery. Pregnant women 
identified as GBS carriers were treated following the CDC guidelines [5]. The 
outcome of their delivery and basic clinical characteristics of their newborns 
were recorded using standardised forms. Newborn body surface (NBS) samples 
(ear and pharyngeal) were additionally collected into Stuart transport media 
within the first 6 hours of life. Newborns who showed any sign of infection were 
transferred and admitted to the neonatology unit of the HER. All children were 
offered a follow-up paediatric consultation after the 10th day of life. Mothers who 
did not bring their children to these consultations were contacted by phone 
during the first month after the birth of their child. Mothers were also 
encouraged to take their babies to the HER and identify themselves as study 
participants if the infants had any symptoms in the first 28 days of life. All infants 
born of participating pregnant women with suspected neonatal invasive infection 
were registered and their clinical data collected. Blood samples for basic sepsis 
screening (including 1 mL for blood culture), NBS (if they were younger than 6 
hours) and cerebrospinal fluid were collected whenever indicated and possible. 
Clinical management of such patients was done according to national 
recommendations.  
In addition, and with the objective of obtaining a complementary picture of the 
aetiology of neonatal sepsis in the same study area during the recruitment 
period, the first three newborns (irrespective of their mothers being or not part of 
the study) admitted every day with suspected invasive infection according to the 
admitting neonatologist (if maternal or guardian's written consent was obtained) 
were also recruited at HER’s neonatology department with the same 
procedures.  
 
Laboratory methods 
Samples were initially analysed in the medical research laboratory of the Centre 
Hospitalier Universitaire Ibn Sina (CHIS). Vagino-rectal swabs were spread onto 
Granada agar specific for GBS isolation. The isolates were identified based on 
colony appearance, Gram stain and standard biochemical tests, using BD 
Phoenix (Becton-Dickinson, USA) whenever necessary. Blood from newborns 
was cultured using BACTEC 9050 (Becton-Dickinson, USA) culture system. 
Minimal inhibitory concentrations (MIC) (mg/L) of erythromycin, clindamycin, 
azythromycin, ampicillin, penicillin G, ceftriaxone, ciprofloxacin, meropenem, 
and vancomycin were determined by E-test (BioMèrieux, France), according to 
CSLI guidelines [10]. Streptococcus pneumoniae ATCC 49619 was used as a 
control strain for disk diffusion antibiotic sensitivity testing. Evaluation of 
potential vaginosis was conducted using Nugent’s score [11]. GBS isolates 
were molecularly characterised at Hospital Clínic, in Barcelona, Spain. Capsular 
typing of GBS isolates was performed by multiplex-PCR [12, 13].  
 
Data management and statistical analysis 
All study questionnaires were manually verified for completeness, with errors 
edited where necessary, and subsequently doubly entered using a program 
written in Filemaker Pro 12 (Filemaker inc., Santa Clara, CA, USA). Statistical 
analyses were done with Stata 14.1 (Stata Corp., College Station, TX, USA). 
Study variables were counted and summarised in frequency tables. Data were 
analysed using the Fisher exact and Chi-square tests. Multivariate analyses 
were conducted using logistic regression methods. A probability of <0.05 was 
considered statistically significant.  
 
 
Results 
During the study, a total of 350 pregnant women and 139 neonates born of 
these women were recruited (Fig. 1). Many of the recruited mothers delivered 
outside of the hospital where they had conducted their antenatal follow-up. 
Additionally, 160 different newborns with suspected clinical sepsis were also 
investigated. For the principal maternal analysis, 349 vagino-rectal and vaginal 
swabs, 347 vaginal smears and urine samples were available. In addition, 136 
ear and pharyngeal cultures from the infants born of these pregnant women 
were available. 
 
Pregnant women’s outcomes 
Mean age of recruited pregnant women was 27 years old [Standard deviation 
(SD) 6.15; range 17-45]. Almost half of them, 47% (165/350), were primiparous. 
Almost 10% (33/350) referred an infection during the current pregnancy, 73% 
(24/33) genital and 27% (9/33) of the urinary tract. 
Nearly a quarter of the pregnant women were GBS colonised (82/349; 24%) 
according to the results of the vagino-rectal swabs. As expected, the positivity 
of GBS in vaginal (only) samples was lower, 8% (26/349), although all women 
who had a positive vaginal sample had also a positive vagino-rectal one.  
Risk factors significantly associated in a univariate analysis with a vagino-rectal 
colonisation with GBS are shown in Table 1. Pregnant women with a history of 
hypertension during the current pregnancy had a significantly higher risk of 
being GBS colonised [Odds ratio (OR) 17.34; 95% confidence interval (CI) 
(1.91,157.07); p<0.001], similarly to pregnant women with vaginal pruritus [OR 
2.30; 95%CI (1.22,4.31); p=0.008].  
No association of Nugent’s score and vaginal pruritus was found (p=0.873), or 
between GBS colonisation and Nugent’s score (Table 1). The observed 
association between vaginal pruritus and GBS colonisation remained 
statistically significant in the group with normal Nugent´s score (p=0.004), but 
not in the groups with intermediate results or overt vaginosis (p=0.745 and 
p=0.533, respectively).  
 
Among the 82 GBS strains isolated from pregnant women, 67 (82%) were 
available for molecular characterisations. Serotypes V, II and III were the most 
frequently isolated, representing 36% (24/67), 25% (17/67) and 18% (12/67) of 
the cases, respectively. The remaining detected serotypes included Ia (6/67, 
9%), IV (5/67, 7%) and IX (3/67, 5%) (Table 2).  
 
Only 6/67 (9%) of the strains were erythromycin-resistant (MIC >256 mg/L), and 
4/67 (6%) clindamycin-resistant (MIC >256 mg/L). All strains were fully (100%) 
susceptible to penicillin.  
When specifically looking at the two more frequent serotypes (II and V), strains 
belonging to serotype II appeared to be susceptible to all the antimicrobial 
agents routinely administered as part of antenatal prophylaxis. In contrast, 
strains belonging to serotype V were more resistant to antimicrobial agents 
[13% (3/24) resistant to clindamycin and erythromycin]. 
 
Outcomes from newborns born of recruited pregnant women  
A total of 139 newborns of the recruited 350 pregnant women (40%) were born 
in the study maternity wards and in 136 (97%) NBS swabs were performed 
(Table 3). Recruited babies were born vaginally in 76% (106/139) of the cases, 
through vaginally instrumented delivery in 13% (18/139) and by Caesarean 
section in 9% (13/139) of the cases. For two of the newborns, no information on 
mode of delivery was available. No differences in newborns’ weight, length, or 
Apgar score at birth were observed in relation to GBS colonisation (data not 
shown). Ten of 136 children (7.4%) had at least one NBS culture positive for 
GBS and eight of them (80%) where available for molecular analysis (Tables 2 
and 3). Two colonised newborns were born of pregnant women with a vagino-
rectal culture negative for GBS. Colonisation of the pregnant women with GBS 
was significantly associated with newborn superficial colonisation (p<0.001). A 
borderline association was observed between colonisation of the pregnant 
woman by E. coli and GBS positive cultures in the newborn (p=0.055). Two of 
the three mothers colonised by E. coli who had a child with GBS colonisation 
were also colonised by GBS. The borderline association between maternal E. 
coli colonisation and GBS colonisation in the newborn must be interpreted with 
caution due to the low numbers, and the confounding effect of simultaneous 
maternal GBS colonisation. All strains were fully susceptible to penicillin, 
erythromycin and clindamycin.  
The most common serotypes presented in pregnant women (II and V) were 
similarly present in infants (Table 2). However serotype IV was significantly 
more frequently isolated in children than among pregnant women (p=0.035) 
perhaps suggesting an association with transmission (Table 2). Other 
comparisons of serotype distribution among the pregnant women group vs. 
newborns with positive blood culture and this group of newborns vs. all 
newborns with any positive peripheral culture were performed, but no significant 
differences were observed (Table 4). None of the children born of pregnant 
women recruited at delivery developed clinical sepsis in the first 48 hours, 
irrespective of NBS results. Only 37 children born of the 82 colonised pregnant 
women were born in the study maternity wards, and 16 of them (43%) were 
followed up during their first month of life with only one being admitted with 
clinical sepsis (no microorganisms were isolated in samples obtained as part of 
the sepsis workup, and evolution was good).  
 Neonatal outcomes in recruited sick newborns with suspected sepsis  
Of the 160 additional recruited newborns with sepsis suspicion in HER, 120 
(75%) were aged less than 24 hours, and overall 154 (96%), were younger than 
seven days.  
Among 160 newborns admitted with clinical sepsis, 158 had blood culture 
results available, and 31 (19%) had cerebrospinal fluid samples for meningitis 
investigation. Among the 158 blood cultures, 15 samples (9%) were positive. 
The isolated bacteria in blood included GBS (5, 3.2%; one case being also 
positive in CSF), S. aureus (6, 3.8%), E. coli (1, 0.6%), K. pneumoniae (1, 
0.6%) and Enterococcus (2, 1.3%). One of these GBS-infected newborns died, 
yielding a case fatality rate for GBS infection of 20%. Among the 78 infants with 
available peripheral cultures, six (8%) infants presented at least one peripheral 
culture with GBS growth. All GBS detected in those infants were penicillin 
susceptible. Information of molecular analysis of the GBS isolated is 
summarised in Table 2.  
 
Discussion 
This study presents the first comprehensive effort to determine the prevalence 
of GBS colonisation, serotype distribution, and associated risk factors for this 
infection during pregnancy in Morocco, a country for which no clear preventive 
measures have been implemented to decrease the burden and morbidity 
associated with vertical GBS transmission. The prevalence of GBS colonisation 
in pregnant women of the study was 24%, similar to previous smaller studies in 
other areas of the country including pregnant women directly in the delivery 
room (20.5% Marrakech; 23.3% Fez) [14, 15]. Such carriage rates were also in 
line with those described in other countries of the Northern African/Middle 
Eastern region (22%), or to more recent data from Sub-Saharan Africa [16-19], 
but generally higher than the overall regional estimate of 18% [18, 19]. 
Importantly, GBS was confirmed as an important cause of neonatal invasive 
bacterial disease, as it was detected in 3% (5/160) of the additional studied 
neonates with suspected neonatal sepsis.  
 
In this study, GBS colonisation was significantly associated with hypertension 
during the current pregnancy. This association has not been reported in similar 
studies conducted elsewhere [15, 16, 20-23]. The association between 
pregnancy-related hypertension and asymptomatic bacteriuria has been known 
[24]. E. coli associated gastrointestinal infections during pregnancy have also 
been linked with maternal hypertension and infection and inflammation may be 
involved in the pathogenesis of preeclampsia [25-28]. The mechanistic of this 
association and the true impact of such a finding need to be confirmed and 
further explored. 
Our study also confirmed an association between GBS carriage and vaginal 
pruritus, an easily detectable clinical symptom. Classically, GBS colonisation 
has been considered asymptomatic [29]. Co-infections could be the cause of 
the pruritus acting as potentially confounding factors, but it seems unlikely 
because no association between GBS and E. coli co-infection or between 
presence of vaginal E. coli and pruritus could be found. Similarly, the 
association persisted even in the group with a normal Nugent’s score, ruling out 
bacterial vaginosis as an alternative explanation. The true meaning of this 
finding, and its potential public health implications, also warrant further research. 
Other reported risk factors of GBS colonisation, such as race, smoking, age, 
diabetes, multiple partners, Candida colonisation, intravaginal cleaning, 
anaemia and seasonality among others were not identified in this study.[16, 17, 
20, 30-34]. This limitation could be partly explained by the low prevalence of 
some conditions in our study (i.e. differences in race) or the heterogeneity of the 
populations evaluated in other studies, which often included non-pregnant 
women, HIV-infected women or pregnant women at other gestational ages [16, 
17, 20, 30-34].  
GBS colonisation in newborns was significantly associated with colonisation in 
their mothers (p<0.001). A positive maternal vaginal culture is the strongest risk 
factor for neonatal infection, which is in concordance with the results of this 
study [29]. It is, however, important to note that two colonised newborns were 
born of pregnant women with a negative vagino-rectal culture. 
 
GBS strains isolated in this Moroccan setting were fully susceptible to penicillin 
and ampicillin, justifying that these two antibiotics remain the first-line treatment 
and prophylaxis option. However, the observed resistance to clindamycin (6%), 
or erythromycin (9%) could constitute a clinical problem in cases of allergy to 
penicillin, as these are the recommended alternatives [5].  
 
Importantly, the previously described association between maternal colonisation 
with GBS and E. coli [16] was not observed in this study. This may be due to 
the lower prevalence of E. coli colonisation, although a borderline association 
was observed between colonisation of the pregnant woman by E. coli and GBS-
positive cultures in the newborn, suggesting that a relationship between both 
bacteria is plausible. This finding, if further confirmed, would have important 
public health implications, as treating GBS/E. coli co-infections with 
penicillin/ampicillin would therefore appear inadequate, as up to 20% of 
circulating E. coli isolates may be resistant to such antimicrobials [35].   
 
Geographical diversity of GBS serotype distribution has been reported over time 
[36-38], with the capsular polysaccharide type III as the major culprit for GBS 
disease, causing more than 60% of all global cases [39]. A pentavalent 
conjugate vaccine including serotypes Ia, Ib, II, III and V could thus prevent 
85%-98% of the global GBS neonatal disease [1, 19]. In Rabat, the two most 
common serotypes were V and II, both clearly related to invasive infection [40], 
closely followed by serotype III. In spite of the differences observed in this 
series, it is important to highlight that such a vaccine, currently under 
development, would have been effective against almost 90% of the colonising 
cases found in this setting, with the other candidate trivalent vaccine being able 
to prevent only 28% of the cases. In this study, serotype IV was observed in 6% 
of colonised pregnant women, similar to data from other countries as Turkey, 
Brazil and United States and lower than in other Middle Eastern countries, such 
as the United Arab Emirates [41-45]. This could suggest that serotype IV is an 
emergent serotype as it was significantly related to transmission and identified 
as cause of invasive disease, suggesting that this non-vaccine serotype could 
play a role in neonatal sepsis in this area. It is important to highlight, however, 
that GBS vaccines have been designed to prevent invasive neonatal disease 
secondary to GBS, rather than to eradicate maternal GBS colonisation. 
Therefore, it is the serotype distribution of invasive neonatal GBS disease that 
should guide the design of any future GBS vaccine. Our findings predominantly 
reflect the distribution of circulating serotypes carried by Moroccan mothers or 
their children but not necessarily that of those responsible for invasive neonatal 
disease, as numbers in this particular group were very small. Larger studies 
better characterising septic infants with confirmed GBS disease in this setting 
are required to confirm the validity of the role of serotype IV and the potential 
repercussions of adding it to any new candidate GBS vaccine.  
A study limitation is the absence of the molecular characterisation of the 
isolates with an analysis by multilocus sequence typing (MLST) that would 
significantly improve the results, as it would allow the comparison of the GBS 
genetic lineages circulating in Morocco with those in other countries. 
Additionally, it would be a valuable indicator for the analysis of vertical 
transmission when comparing the pregnant woman/neonate pairs.  
 
Conclusions 
GBS maternal colonisation in Rabat occurs in almost a quarter of pregnancies, 
and vertical transmission of this pathogen can therefore be a real but 
preventable threat to their offspring. Considering the high prevalence of GBS 
colonisation, the adequate acceptability of the screening procedures, the 
absence of easily identifiable risk factors and the insufficiency of the current 
intrapartum risk factor policy, universal screening would be an acceptable 
option in Morocco. A cost-effectiveness and feasibility study should be 
conducted in order to evaluate whether universal screening of GBS during 
pregnancy is warranted, mirroring what is done in other parts of the world. Such 
a strategy could be a temporary solution in anticipation of the much-awaited 
pentavalent GBS maternal vaccine. 
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Figure 1: Study flow-chart 
 
   
 
 
 
 
 
 
  
 
 
 
 
 
 
  
 
 
 
 
 
 
  
   
 
 
 
 
 
*Recruitment started during working hours but because delivery was prolonged, 
children were born during the weekend when the laboratory was not available 
and some information was lost. 
 
 
  
Antenatal 
consultations for 
high-risk 
pregnancies 
General antenatal 
consultations 
 
Delivery room 
92 eligible pregnant women  144 eligible pregnant 
women 
116 eligible pregnant 
women 
90 pregnant women 
recruited 
144 pregnant women 
recruited 
116 pregnant women 
recruited 
16 newborns from 15 mothers 
detected upon delivery and with 
available information  
21 newborns from 21 mothers 
detected upon delivery and with 
available information  
 
102 newborns with 
information available 
2 consent refusals 0 consent refusals 
75 women delivered 
elsewhere or not identified  
0 consent refusals 
123 women delivered 
elsewhere or not identified  
14 newborns lost, due to 
prolonged delivery* 
160 newborns with sepsis suspicion 
recruited and studied for group B 
Streptococcus  
National referral 
children’s hospital 
Table 1: Risk factors for vagino-rectal GBS colonisation in pregnant women, according to the 
univariate analysis 
 
Variables GBS (+) n (%) GBS (-) n (%) p-value* 
Recruitment place 
High-risk antenatal consultation 
General antenatal consultation 
Delivery room 
 
25 (30.49) 
27 (32.93) 
30 (36.59) 
 
65 (24.34) 
116 (43.45) 
86 (32.21) 
0.226
#
 
Medical insurance 
Yes 
No 
 
61 (74.39) 
21 (25.61) 
 
210 (78.65) 
57 (21.35) 
0.418
#
 
Pregnant women education 
None 
Primary 
Secondary 
University 
 
12 (14.81) 
22 (27.16) 
36 (44.44) 
11 (13.58) 
 
38 (14.34) 
70 (26.42) 
117 (44.15) 
40 (15.09) 
0.989
#
 
Partner’s education 
None 
Primary 
Secondary 
University 
 
4 (5.00) 
22 (27.50) 
44 (55.00) 
10 (12.50) 
 
25 (9.62) 
59 (22.69) 
139 (53.46) 
37 (14.23) 
0.516
#
 
Pregnant women age (years) 
< 20  
20-29 
≥ 30 
 
4 (4.88) 
39 (47.56) 
39 (47.56) 
 
6 (2.25) 
140 (52.43) 
121 (45.32) 
0.392
#
 
Parity 
Primiparous 
Multiparous 
 
43 (52.44) 
39 (47.56) 
 
121 (45.32) 
146 (54.68) 
0.258
#
 
Use of antibiotics during pregnancy 
Yes 
No 
 
3 (3.66) 
79 (96.34) 
 
14 (5.24) 
253 (94.76) 
0.560
#
 
Vaginal cleansing 
Yes 
No 
 
16 (19.51) 
66 (80.49) 
 
48 (17.98) 
219 (82.02) 
0.753
#
 
Number of antenatal consultations 
0 
1-3 
>3 
 
2 (2.44) 
35 (42.68) 
45 (53.56) 
 
10 (3.75) 
114 (42.70) 
143 (53.56) 
0.847
#
 
Anaemia 
Yes 
No 
 
14( 17.07) 
68 (82.93) 
 
52 (19.48) 
215 (80.52) 
0.627
#
 
Gestational diabetes 
Yes 
No 
 
5 (6.10) 
77 (93.90) 
 
13 (4.87) 
254 (95.13) 
0.660
#
 
 Hypertension during pregnancy 
Yes 
No 
 
5 (6.10) 
77 (93.90) 
 
1 (0.37) 
266 (99.63) 
0.003
§
 
Infection during pregnancy 
Yes 
No 
 
8 (9.76) 
74 (90.24) 
 
25 (9.36) 
242 (90.64) 
0.915
#
 
Leucorrhoea 
Yes 
No 
 
20 (24.39) 
62 (75.61) 
 
64 (23.97) 
203 (76.03) 
0.938
#
 
Vaginal pruritus 
Yes  
No 
 
20 (24.39) 
62 (75.61) 
 
33 (12.36) 
234 (87.64) 
0.008
#
 
Dysuria 
Yes 
No 
 
10 (12.20) 
72 (87.80) 
 
27 (10.11) 
240 (89.89) 
0.592
#
 
E. coli colonisation    
Yes 
No 
5 (6.10) 
77 (93.90) 
34 (12.73) 
233 (87.27) 
0.095
#
 
Bacterial vaginosis 
Normal 
Intermediate 
Vaginosis  
 
63 (79.75) 
14 (17.72) 
2 (2.53) 
 
219 (82.95) 
33 (12.50) 
12 (4.55) 
 
0.389
#
 
GBS in newborn 
At least one positive culture 
Negative 
No culture available 
 
8 (9.8) 
28 (34.2) 
46 (56) 
 
2 (0.75) 
94 (35.6) 
168 (63.6) 
< 0.001
§
 
*: p value of the comparison between the first two columns; #: Pearson chi-square; §: Fisher’s 
exact test; ƚ: 3 additional children with negative culture did not have mother’s result available. 
Bold characters: statistically significant. GBS: Group B streptococcus 
 
  
Table 2: Distribution of the different serotypes among Group B streptococcus strains isolated 
from pregnant women and newborns 
 
*:Vagino-rectal or vaginal samples of pregnant women which strains were available for 
molecular analysis; #: Peripheral samples of colonised newborns born of recruited mothers 
which strains were available for molecular analysis; §: Infants recruited at the neonatal intensive 
care unit with clinical sepsis and with at least one newborn body surface (NBS) sample positive 
to Group B streptococcus and available for molecular analysis; ƚ: Infants recruited at the 
neonatal intensive care unit with clinical sepsis and blood culture positive to Group B 
streptococcus; α: Fisher’s exact test; A probability of <0.05 was considered statistically 
significant. Bold characters: statistically significant. 
 
  
Variables 
Data from mother and 
newborns recruited at the 
maternity 
 
p 
Data from newborns admitted 
to the hospital with clinical 
sepsis suspicion 
 
p Colonised 
mothers* 
Colonised 
newborns# 
Newborns with 
at least one 
positive NBS
§
 
Newborns 
with 
positive 
GBS blood 
culture
ƚ
 
Serotype N=67 N=8  N=6 N=5  
Ia 6 (9%) 0 (0%) 1.000
α
 0 (0%) 0 (0%) 1.000
α
 
II 17 (25%) 2(25%) 1.000
α
 2 (33%) 2 (40%) 1.000
α
 
III 12 (18%) 0 (0%) 0.341
α
 0 (0%) 1 (20%) 0.455
α
 
IV 5 (7%) 3 (38%) 0.035
α
 1 (17%) 1(20%) 1.000
α
 
V 24 (36%) 3 (38%) 1.000
α
 3 (50%) 1 (20%) 0.545
α
 
IX 3 (5%) 0 (0%) 1.000
α
 0 (0%) 0 (0%) 1.000
α
 
Table 3: Body surface cultures results among infants with available samples, according to 
recruitment place 
 High-Risk 
antenatal 
consultation 
General antenatal 
consultation 
Delivery room Total HER 
Nº of recruited 
mothers  
90 144 116 350 160
*
 
Infants with available 
NBS swabs 
15 (17%) 20 (14%) 101 (87%) 136 (39%) 78 (49%) 
Results
#
  
GBS positive 3 (20%) 0 (0%) 7 (6.93%) 10 (7.35%) 6 (8%) 
E. coli positive 0 (0%) 2 (10%) 12 (11.88%) 14 (10.29%) 7 (9%) 
K. pneumoniae 
positive 
0 (0%) 0 (0%) 3 (2.97%) 3 (2.20%) 1 (1%) 
Negative 12 (80%) 18 (90%) 79 (78.22%) 109 (80.14%) 64 (82%) 
 
Abbreviations: NBS: newborn body surface, GBS: Group B streptococcus HER: Rabat 
children’s hospital; *: Total of children recruited with clinical sepsis. #: At least one out of two 
newborn body surfaces positive 
 
  
  
 
1 
Table 4: Comparison of serotype distribution among pregnant women group vs. newborns with 
positive blood culture and newborns with positive blood culture vs. all newborns with any 
positive peripheral culture. 
 2 
*:Vagino-rectal or vaginal samples from colonised pregnant women which strains were available 3 
for molecular analysis; ƚ: Infants recruited at the neonatal intensive care unit with clinical sepsis 4 
and blood culture positive to Group B streptococcus $: Peripheral samples Group B 5 
streptococcus positive from asymptomatic infants born of pregnant women and peripheral 6 
samples Group B streptococcus positive from infants recruited in the neonatal intensive care 7 
unit which strains were available for molecular analysis. α: Fisher’s exact test; A probability of 8 
<0.05 was considered statistically significant.  9 
 10 
 
Mothers
*
 
Newborns with 
positive blood 
culture ƚ 
p 
Newborns with 
positive blood 
culture ƚ 
Newborns with 
any positive 
peripheral 
culture
$
 
p 
Serotype N=67 N=5  N=5 N=14  
Ia 6 (9%) 0 (0%) 0.639
α
 0 (0%) 0 (0%) -- 
II 17 (25%) 2 (40%) 0.397
α
 2 (40%) 4 (29%) 0.520
α
 
III 12 (18%) 1 (20%) 0.642
α
 1 (20%) 0 (0%) 0.263
α
 
IV 5 (7%) 1 (20%) 0.361
α
 1 (20%) 4 (29%) 0.603
α
 
V 24 (36%) 1 (20%) 0.428
α
 1 (20%) 6 (43%) 0.366
α
 
IX 3 (5%) 0 (0%) 0.803
α
 0 (0%) 0 (0%) -- 
